Board of Directors

The GI Dynamics board is committed to carrying out our mission of improving the lives of people suffering from the global epidemics of type 2 diabetes and obesity through the development and commercialization of breakthrough treatments.


Daniel J. Moore (Chairman)

Daniel Moore is Chairman of the Board for LivaNova [NASDAQ: LIVN]. Mr. Moore previously held the position as president and chief executive officer of Cyberonics [NASDAQ: CYBX] from 2007 to 2015, when the company merged with Sorin to form LivaNova. Mr. Moore joined Cyberonics after 18 years at Boston Scientific [NYSE: BSX] where he was the president of InterContinental. He also serves on the boards of the Epilepsy Foundation of America, BioHouston and the Advisory Board of Purdue University’s Weldon School of Biomedical Engineering.

Prior company boards include TriVascular [NASDAQ: TRIV] which was sold to Endologix and Topera which was sold to Abbott. He also served on the boards of BrainScope Company, Inc., Medical Device Manufacturers Association (past-Chair), Medical Device Innovation Consortium, Epilepsy Foundation of Texas (past- Chair) and Smiling Kids Inc.


Oern Stuge, MD, MBA

Oern Stuge, MD, MBA, brings significant experience in medical devices and specifically in type 2 diabetes and obesity. He has also lead successful clinical development programs and global commercialization efforts and has held executive and board positions with numerous medical device companies over the past 30 years. As director, he has helped lead several successful company exits, raised significant capital and launched an IPO.


Timothy J. Barberich

Timothy Barberich has nearly 40 years’ experience in pharmaceutical and medical device companies, in technical, sales, marketing and management positions, including chief executive officer and chairman of the board.

Mr. Barberich is founder and former Chairman and CEO of Sepracor Inc., a research-based pharmaceutical company which was acquired by Dainippon Sumitomo Pharma Co., Ltd. in 2009, now known as Sunovion Pharmaceuticals. Mr. Barberich served as CEO of Sepracor from 1984 to 2007 and as Chairman of the Board from 1990 to 2009. He currently serves on the board of directors of publicly-traded, Verastem Inc. [NASDAQ: VSTM], and on the boards of the privately held companies, Frequency Therapeutics, and TScan Therapeutics. He has previously served on the boards of several public and private biotech and medical device companies. Mr. Barberich has also served on the board of trustees of Boston Medical Center and as a member of the board of the Pharmaceutical Research and Manufacturers’ Association (PhRMA). Prior to founding Sepracor, Mr. Barberich spent 10 years as a senior executive at Millipore Corporation. 

Mr. Barberich is a graduate of King’s College and holds a Bachelor of Science degree in Chemistry.


Juliet Thompson

Juliet Thompson has advised and raised capital for healthcare companies for more than 20 years and founded Code Securities, a healthcare investment banking firm that was sold to Nomura. In addition to GI Dynamics, Ms. Thompson also serves as NED for Nexstim Limited, NED for Novacyt SA, and is the chair of Premier Veterinary Group Plc.